-
Lenalidomide, sold
under the
brand name
Revlimid among others, is a
medication used to
treat multiple myeloma,
smoldering myeloma, and myelodysplastic...
- 83% at 30 months,
lenalidomide plus low-dose
dexamethasone an 82%
survival at 2 years, and melphalan, prednisone, and
lenalidomide had a 90% survival...
-
blood cells, and antibiotics. Drug
therapy may
include the
medications lenalidomide,
antithymocyte globulin, and azacitidine. Some
people can be
cured by...
-
imide group. The IMiD
class includes thalidomide and its
analogues (
lenalidomide, pomalidomide,
mezigdomide and iberdomide).
These drugs may also be referred...
-
humanized IgG1
monoclonal antibody medication used in
combination with
lenalidomide and dexamethasone, for
adults that have
received 1 to 3
prior therapies...
-
including treatment with
bortezomib and an
immunomodulatory therapy (such as
lenalidomide) and have
demonstrated disease progression on or
within 60 days of completion...
-
months (in the placebo+
lenalidomide+dexamethasone
study arm
including 362 people) to 20.6
months (under ixazomib+
lenalidomide+dexamethasone, 360 people)...
- that
makes cancer and
immunology drugs. Its
major product is
Revlimid (
lenalidomide),
which is used in the
treatment of
multiple myeloma, and also in certain...
-
under the
brand name Monjuvi, is a
medication used in
combination with
lenalidomide for the
treatment of
adults with
relapsed or
refractory diffuse large...
- for
multiple myeloma show
great promise in
combination therapy with
lenalidomide and dexamethasone, as well as with
bortezomib and dexamethasone.[needs...
